Company intelligence / Profile preview

YoungHeartValve

Ownership: Private
Development stage: Preclinical

Overview

YoungHeartValve is developing next-generation, hyaluronan-enhanced polymeric transcatheter aortic valves designed to be more durable and biocompatible than current options. Their technology aims to eliminate the need for animal tissue, reduce calcification and thrombosis risk, and avoid long-term anticoagulation therapy. Preclinical testing has demonstrated durability over 200,000+ cycles with promising acute and chronic test results.

Therapeutic areas: Cardiovascular
Modalities: DeviceBiopolymer-based device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Rejuvenate

Pre-clinical

Indications: Aortic valve stenosis, Aortic valve regurgitation

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on YoungHeartValve.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YoungHeartValve.

Explore the full profile